A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

NCT00485732 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL: HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
BIOLOGICAL: Placebo

Sponsor

GlaxoSmithKline